Injectable docetaxel composition and preparation method therefor - Patents.com
A docetaxel formulation using cyclodextrin and alternative solvents overcomes safety risks and solubility issues, achieving high solubility and stability without polysorbate or ethanol, ensuring safe and effective clinical use.
Patent Information
- Application Number
- JP2023030824
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-07-25
- Filing Date
- 2023-03-01
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2038-08-02
AI Technical Summary
Current docetaxel formulations using polysorbate 80 and ethanol pose significant safety risks due to adverse effects such as anaphylaxis and irritation, and ethanol intoxication, while ethanol-free formulations face solubility and stability issues, leading to precipitation and clinical impracticality.
A docetaxel composition using cyclodextrin, a co-solvent (other than ethanol), stabilizers, and additives, prepared without polysorbate or ethanol, achieving solubility greater than 10 mg/mL and stability for over 4 hours, with methods including stirring and high-pressure homogenization to ensure safety and efficacy.
The composition significantly reduces adverse effects, enhances solubility and stability, allowing for safe and convenient clinical use without the need for pre-medication, meeting clinical requirements and extending stability to over 24 months.
Smart Images

Figure 0007577364000001 
Figure 0007577364000002 
Figure 0007577364000003
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of medicine. In particular, the present invention relates to an injectable composition containing docetaxel and a method for preparing the same. [Background technology]
[0002] Docetaxel is a white or nearly white powder that is practically insoluble in water, soluble in ethanol, and unstable in alkaline conditions. The chemical name of docetaxel is [2aR-(2aα,4β,4aβ,6β,9α,(aR*,βS*),11α,12α,12aα,12bα)]-β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxybenzenepropanoic acid [12b-acetyloxy-12-benzoyloxy-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6, 11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca-[3,4]benz[1,2-b]oxet-9-yl] ester.
[0003] Additionally, docetaxel has the following structural formula: TIFF0007577364000001.tif40128 and its molecular formula is C 43 H 53 NO 14 and Its molecular weight is 807.89.
[0004] Docetaxel is a taxane antitumor drug that can be semisynthetically prepared from precursors extracted from yew. Its anticancer mechanism of action and characteristics are similar to those of paclitaxel, and it belongs to microtubule inhibitors. Docetaxel blocks cancer cells in the G2 and M phases and inhibits mitosis and proliferation of cancer cells through promoting the assembly of tubulin dimers into microtubules and preventing the depolymerization process to stabilize microtubules. Docetaxel has stronger pharmacological effects than paclitaxel. Specifically, compared with paclitaxel, docetaxel has three times higher intracellular concentration and longer intracellular retention time. The affinity of docetaxel for microtubules is two times higher than that of paclitaxel; docetaxel is twice as active as paclitaxel when it acts as a microtubule stabilizer and assembly promoter; and docetaxel is twice as active as paclitaxel when it acts as a microtubule depolymerization inhibitor. In vitro antitumor activity tests have shown that docetaxel is 1.3 to 12 times more active than paclitaxel. In addition, clinical studies have shown that docetaxel is more effective in anthracycline-resistant breast cancer compared to paclitaxel. Docetaxel is a highly effective drug in the second-line treatment of anthracycline-resistant breast cancer, and is also one of the most effective drugs in monotherapy and combination chemotherapy for non-small cell lung cancer.
[0005] The current formulation of docetaxel in use is an injection solution that includes a single preparation package (containing Tween 80 and / or ethanol) and a diluent (13% ethanol in water). The earliest original product of docetaxel is a semi-synthetic antineoplastic drug developed by Sanofi-Aventis (formerly Rhone-poulenc Rorer in France), and was first marketed in Mexico, South Africa, and Canada in 1995 as a second-line treatment for advanced breast cancer and non-small cell lung cancer. In 1996, docetaxel was approved by the US FDA for the treatment of metastatic breast cancer after chemotherapy failure and metastatic non-small cell lung cancer after platinum failure. In December 2000, docetaxel in combination with cisplatin was approved by the FDA as a first-line therapy for locally advanced or metastatic non-small cell lung cancer. At present, docetaxel is approved for sale in nearly 100 countries and regions around the world, including China, Europe, the United States, and Japan.
[0006] Docetaxel is lipophilic and practically insoluble in water, so its original formulation, TAXOTERE®, uses the surfactant polysorbate 80 (Tween 80, T-80) as a solubilizing agent and ethanol as a diluent. The packaging specifications of the formulation contain two vials: (a) TAXOTERE® Injection, 20 mg docetaxel dissolved in 0.5 mL polysorbate 80; (b) Diluent, about 1.5 mL of 13% (w / w) ethanol solution. However, for such a formulation of docetaxel, a two-step preparation process is required before administration to patients: the first step is to mix TAXOTERE® Injection (a) with the diluent (b) to obtain a mixture with a concentration of about 10 mg / mL; the second step is to dilute the mixture obtained by the first step into a 250 mL container (non-PVC) containing either a 0.9% sodium chloride solution or a 5% glucose solution for injection. The concentration of docetaxel in the prepared final infusion solution should be between 0.35 mg / mL and 0.70 mg / mL and should not exceed 0.9 mg / mL.
[0007] In later improved formulations, docetaxel, T-80 and ethanol (with or without) and other carriers are formulated in a single non-aqueous solution. However, to date, there have been no reports of docetaxel formulations that contain neither T-80 nor ethanol, and no literature describes such formulations.
[0008] Polysorbate (Tween), a non-ionic surfactant with a characteristic odor, warm color, and slightly bitter taste, is a series of partial fatty acid esters of polyoxyethylene sorbitol. Polysorbates are widely used as emulsifiers and solubilizers for oils. Polysorbates are generally considered to be non-toxic and non-irritating substances, and are often used as solubilizing carriers in injections of poorly soluble drugs. However, Tween injections can cause adverse effects, for example, it can cause hemolysis at low concentrations (0.01-2.0%), and hypersensitivity reactions can occur during local and intramuscular injections, and in severe cases, severe hypersensitivity reactions characterized by generalized rash / erythema, hypotension and / or bronchospasm, or even fatal anaphylaxis or death, although very rarely. To reduce the adverse effects of polysorbates, patients are clinically required to be premedicated with antihistamines, corticosteroids and H2 antagonists, which greatly reduces compliance with clinical use.
[0009] The presence of polysorbate 80 in docetaxel formulations may cause severe adverse effects, and severe adverse effects characterized by generalized rash / erythema, hypotension and / or bronchospasm, or extremely rarely fatal anaphylaxis have been reported in patients. To reduce the adverse effects caused by polysorbate 80, antihistamines, corticosteroids and H2 antagonists are pre-administered to patients 30 minutes before administration of TAXOTERE®. In addition, two-step dilution is required for TAXOTERE® before clinical use. That is, TAXOTERE® should be diluted first with 13% (w / w) ethanol solution and then with 0.9% sodium chloride solution or 5% glucose solution before administration, which not only leads to complicated steps but also brings safety risks in the use of the drug.
[0010] At the same time, the high concentration of ethanol in docetaxel formulations, which use 13% (w / w) ethanol solution as a diluent or as a co-solvent, may cause greater irritation, intoxication, and other adverse effects during injection and administration of docetaxel formulations. On June 20, 2014, the U.S. Food and Drug Administration (FDA) warned that the intravenous chemotherapy drug docetaxel, which contains ethanol, also known as alcohol, may cause patients to experience intoxication or intoxication during and after treatment. We are reviewing the labels of all docetaxel drugs to avoid this risk. Healthcare professionals should consider the alcohol content of docetaxel when prescribing or administering this drug to patients (especially in patients who must avoid or minimize alcohol intake) and when combining it with other medicines (https: / / www.fda.gov / Drugs / DrugSafety / ucm401752.htm#tabs-6).
[0011] It can be seen that the current docetaxel formulations themselves still pose significant clinical risks in terms of the adverse effects caused by T-80, and / or the greater irritation and intoxication caused by ethanol, and / or the risk of intoxication / drunkenness as warned by the FDA on the label of docetaxel containing ethanol. Therefore, the development of a formulation of docetaxel that does not contain T-80 or ethanol has a very clear clinical advantage, as it would greatly improve patient safety and compliance during the use of the formulation.
[0012] At the end of the 20th century, the combination of nanotechnology and pharmacology gave rise to nanodrugs, i.e., drugs and carriers were formulated into drug-loaded particles (e.g., nanoparticles, nanoliposomes, nanoemulsions) or drug nanocrystals with diameters ranging from 1 to 1000 nm.
[0013] Nanocrystal technology refers to reducing the particle size of micron-sized drug particles to the submicron level (100-1000 nm) or even to the nanometer level (1-100 nm) by means of physical crushing, encapsulation, destruction and dispersion, precipitation crystallization, etc., thereby solving the technical problem of reducing the particle size of poorly soluble drugs to the nanometer level. Nanocrystal technology can effectively improve the solubility and bioavailability of drugs due to the advantages of reducing the particle size of drugs, increasing the specific surface area, saturation solubility and membrane permeability of drugs, as well as extending the retention time at the absorption site. Therefore, this provides a new solution to overcome the problem of poor oral absorption of poorly soluble drugs, and a preparation technology that is stable under the action of stabilizers.
[0014] According to the preparation method, pharmaceutical nanocrystal technology can be classified into milling, crystallization, high-pressure homogenization, emulsification, etc. Meanwhile, pharmaceutical nanocrystal technology also provides a novel solubilization method for poorly soluble drugs for injection. For example, the aqueous solubility of a drug can be increased through nano-milling to reduce the particle size and increase the surface area of the drug; or the aqueous solubility of a drug can be improved by high-pressure homogenization, specifically, the high-pressure environment can facilitate the microparticle formation of the API, and homogenization can accelerate the dissolution of the drug by accelerating the uniform dispersion in the solvent, and the combination of the two techniques can further increase the solubility of poorly soluble drugs.
[0015] Cyclodextrin, a kind of pharmaceutical carrier, has a hollow, hydrophobic, stereochiral space, and its structural feature of "interior hydrophobicity and exterior hydrophilicity" allows it to encapsulate a wide variety of organic small molecules (substrates) with suitable space size to form non-covalent host-guest complexes (inclusion complexes). The most prominent pharmacological effect of cyclodextrin is found to be to increase the aqueous solubility and stability of poorly soluble drugs.
[0016] In the prior art, some patents and / or literature have reported cyclodextrin / docetaxel compositions that do not contain T-80: for example, Patent No. US8765716B2 / CN100411688C (Patent Document 1) (Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and preparation process thereof) invented by Ren Yong et al. discloses a composition containing docetaxel, cyclodextrin and pharma- ceutical acceptable excipients, in which the mass ratio of docetaxel to cyclodextrin is 1:10-1:150. According to the contents disclosed in the specification and claims of this patent, ethanol is used as a co-solvent in the preparation method of the composition, which is then removed under reduced pressure to form a liquid or solid inclusion complex with a small or trace amount of ethanol, in which the content of ethanol is less than 1.0%. Cyclodextrin has a special spatial structure that has a certain inclusion effect on ethanol, so once ethanol enters this space, it is impossible to completely remove it with existing decompression technology. 1 The 1 H NMR also disclosed that "the ethanol methyl peak was weak. Therefore, it can be concluded that in a composition consisting of docetaxel, cyclodextrin and a pharma- ceutically acceptable excipient, the pharma-ceutically acceptable excipient must be a combination of ethanol and other excipients, and compositions prepared therefrom will necessarily contain small or trace amounts of ethanol.
[0017] Patent No. CN1222321C / WO1999 / 024073 (Patent Document 2) (Pharmaceutical Composition Containing Cyclodextrin and Taxoid) invented by GECZY JOSEPH M discloses a composition containing taxoid and cyclodextrin, in which the weight ratio of taxoid to cyclodextrin is between 1:25 to 1:250; Similarly, the preparation method of this composition uses ethanol as a solvent, which is then removed under reduced pressure. In this regard, due to the structural characteristics of cyclodextrin mentioned above, a small amount of ethanol should be contained in this composition.
[0018] Patent No. US2005 / 0009783 (Inclusion Complex of Taxol and 2-Hydroxypoxypropyl-beta-cyclodextrin) invented by Kagkadis discloses a composition containing taxol and its derivatives and 2-hydroxypropyl-beta-cyclodextrin in a molar ratio of 1:1000, again using ethanol in the preparation method.
[0019] The patents discussed above do not use T-80, but do necessarily use ethanol to aid solubilization. However, some ethanol will still remain in the composition even after subsequent removal under reduced pressure. As a result, the composition can only exist in solid form after removal of the ethanol, requiring an additional dilution step before use. It is seen that a liquid form convenient for clinical use cannot be obtained through the above patents. On the other hand, as disclosed in the above patents using ethanol and cyclodextrin to solubilize the taxoid, all compositions disclosed therein are prepared into solid form by removing ethanol. During reconstitution of the compositions disclosed in the above patents, ethanol is required to stabilize the composition in liquid form, since the stability time of the taxoid is greatly reduced in ethanol-free solutions and will generally precipitate within 24 hours. For example, patent application WO2016 / 149162 (Patent Document 4) invented by ZHAO William W et al. (Pharmaceutical Compositions Containing Taxane-Cyclodextrin Complexes, Manufacturing Methods and Methods of Use) clearly discloses that ethanol must be included in the composition, and that the mass ratio of ethanol to taxoid is 5:1 to 40:1. Although a liquid pharmaceutical composition in which taxoids can be stable for a long time is prepared according to this patent, it is understood that the large amount of ethanol contained therein may pose a risk to clinical drug application.
[0020] In Patent No. US6284746 (Inclusion complex of Taxol or Taxotere of Yew extract formed with cyclodextrin, its preparation and use) invented by Lajo Szente et al., complex of paclitaxel or docetaxel or yew extract is directly prepared by using aqueous solution or buffer of cyclodextrin and cyclodextrin derivative, or solution containing small amount of ethanol.However, the maximum water solubility of API in the above prepared complex does not exceed 1mg / mL, which shows that it is difficult to prepare formulation of docetaxel that meets clinical concentration requirement without using ethanol or using very small amount of ethanol.
[0021] After analyzing and studying the above patents, it can be concluded that T-80 can be omitted during the preparation of stable docetaxel / cyclodextrin compositions in liquid form, but ethanol is one that must be used or present.
[0022] Considering the anaphylaxis caused by T-80 in docetaxel formulations and the adverse effects caused by ethanol, it would be a major technological breakthrough if a docetaxel formulation containing neither T-80 nor ethanol could be prepared in a stable liquid form.
[0023] Since ethanol is routinely used in the prior art, it is possible to draw the obvious conclusion that without the use of ethanol, docetaxel compositions containing cyclodextrin cannot be formulated into stable liquid formulations, nor can they be formulated into solid compositions containing low or trace amounts of ethanol.
[0024] However, without being influenced by the above-mentioned conventional practices, and without relying on a special combination formulation and a special preparation method, the inventors of the present application have conducted numerous experiments to prepare a long-term stable liquid docetaxel / cyclodextrin composition and a completely ethanol-free solid composition. The composition prepared by the present invention has neither T-80 nor ethanol, and does not use ethanol in its preparation method. [Prior art documents] [Patent documents]
[0025] [Patent Document 1] US8765716B2 / CN100411688C [Patent Document 2] CN1222321C / WO1999 / 024073 [Patent Document 3] US2005 / 0009783 [Patent Document 4] WO2016 / 149162 [Patent Document 5] US6284746 Summary of the Invention
[0026] In this regard, existing docetaxel preparations have the following drawbacks: ethanol and / or polysorbate used to dissolve or increase the solubility of docetaxel in the formulation may result in severe anaphylaxis, greater irritation and intoxication; in addition, if the docetaxel composition is not solubilized by ethanol, docetaxel has extremely low solubility and does not reach the concentration required in clinical practice, and as a result, the formulation product cannot be prepared; or, the stability time of the docetaxel composition not solubilized by ethanol is relatively short (generally <4 hours) after dilution into an injection solution, and precipitation may occur during clinical use, which poses safety risks in the use of the composition.
[0027] However, the present inventors have overcome the prejudice that ethanol is often used to aid the dissolution of docetaxel in the prior art, and have found the liquid composition of the present invention, which contains cyclodextrin and other specific co-solvents (not ethanol), stabilizers and additives, and is prepared through the method for preparing liquid formulations that is often used in the prior art (the first method of the present invention).In addition, the present inventors have also found that a longer preparation time is required when preparing a high-concentration composition that meets clinical use requirements through the first method.Taking into account the production cost and the risk of microbial and impurity incorporation caused by the longer preparation time, the present inventors have developed the second method, the third method, and the fourth method by continuing to improve the preparation method.
[0028] Specifically, the inventor of the present application constructs a solution system consisting of docetaxel, co-solvent (not ethanol), cyclodextrin, stabilizer, additive (such as citric acid) and a suitable amount of water. In the system, the solubility of docetaxel is ≧10mg / mL (which can meet the general clinical use requirements), and the maximum solubility of docetaxel can reach 40mg / mL. Meanwhile, the GC method is used to determine whether there is ethanol in the system, and the result shows that no ethanol is detected. The solution system of the present invention can be stable for more than 4 hours after reconstitution, which indicates that it can be stably stored for a long time.
[0029] The stability of the solution system of the present invention is embodied in the following aspects: (1) when samples obtained in some preferred embodiments are stored under conditions of 25°C±2°C and RH 60%±5% for 24 months, no crystalline precipitation of docetaxel is observed; (2) all the indicators of the samples stored under conditions of 25°C±2°C and RH 60%±5% for 24 months meet the requirements for injection solutions, and their impurity limits meet the USP standards; (3) the samples are clear and colorless while standing, and no crystalline precipitation is observed. Therefore, the liquid samples of the present application can be stored extremely stable for 24 months, and the solid samples of the present application can be stable for over 24 hours after reconstitution.
[0030] In other words, the inventors of the present application have overcome the prejudices of the prior art and arrived at an unobvious and even unexpected result by using a series of preparation methods: a novel composition comprising docetaxel, cyclodextrin, a co-solvent (not ethanol), a stabilizer and an injection additive. Furthermore, the composition found by the inventors does not contain polysorbate or ethanol, and does not use ethanol in its preparation method, but even without the use of ethanol or polysorbate, the present invention can still significantly improve the characteristics of docetaxel formulations.
[0031] The inventors of the present invention have found in research that by using this composition, which contains docetaxel, cyclodextrin, cosolvent (not ethanol), stabilizer and additive, but does not contain polysorbate and ethanol, it can avoid the adverse effects caused by polysorbate, and reduce the irritation caused during injection of the composition, as well as the toxicity and adverse effects caused during administration.In addition, the present invention provides a docetaxel formulation with greatly improved stability, i.e., a stable injection form without ethanol for docetaxel, and convenience for clinical use.
[0032] At the same time, the technical solution provided by the present application overcomes the following shortcomings described in patent US6284746: the maximum solubility of taxane in the composition cannot reach about 1.0 mg / ml without using ethanol and polysorbate, and therefore cannot meet the concentration requirements for clinical use.On the contrary, the present invention provides a method that can greatly increase the solubility of taxane without using ethanol and polysorbate, which is not only a breakthrough but also a technical innovation over the prior art, effectively solving the problem of clinical practicality of drugs containing taxane.
[0033] In view of the technical problems in the prior art, the objective of the present invention is to provide a formulation of docetaxel that does not contain polysorbate and ethanol. The formulation of the present invention, which is in the form of injection or lyophilized powder, has stable quality characteristics, can meet the requirements for clinical use, and can ensure safety and efficacy during administration.
[0034] The technical solutions provided by the present invention are as follows:
[0035] In one aspect, the present invention provides an injectable composition containing docetaxel, the composition comprising the following components (in parts by weight): 1 part docetaxel, 20-60 parts cyclodextrin, 5-80 parts cosolvent, 0-20 parts stabilizer 1, 0.2-30 parts stabilizer 2, 0.001-1.0 parts additive and is ethanol and polysorbate free, and no ethanol is used in its preparation.
[0036] Preferably, the composition comprises the following components (in parts by weight): 1 part docetaxel, 25-50 parts cyclodextrin, 20-70 parts cosolvent, 0-10 parts stabilizer 1, 1-15 parts stabilizer 2, 0.001-0.5 parts additive and is free of ethanol and polysorbate, and no ethanol is used in its preparation.
[0037] More preferably, the composition comprises the following components (in parts by weight): 1 part docetaxel, 25-40 parts cyclodextrin, 40-70 parts co-solvent, 0-5 parts stabilizer 1, 4-9 parts stabilizer 2, 0.001-0.4 parts additive and is ethanol and polysorbate free, and no ethanol is used in its preparation.
[0038] More preferably, the composition comprises the following components (in parts by weight): 1 part docetaxel, 30-40 parts cyclodextrin, 50-65 parts co-solvent, 1-2 parts stabilizer 1, 5-8 parts stabilizer 2, 0.001-0.3 parts additive and is ethanol and polysorbate free, and no ethanol is used in its preparation.
[0039] Preferably, the cyclodextrin includes, but is not limited to, sulfobutylether-β-cyclodextrin (SBE-β-CD), hydroxypropyl-β-cyclodextrin (HP-β-CD) and / or hydroxypropyl-sulfobutylether-β-cyclodextrin (HP-SBE-β-CD); more preferably, the cyclodextrin is HP-β-CD or SBE-β-CD; even more preferably, the cyclodextrin is SBE-β-CD.
[0040] Preferably, the co-solvent is one or more selected from, but not limited to, polyethylene glycol (PEG), propylene glycol and glycerol, and the co-solvent is not ethanol; more preferably, the co-solvent is polyethylene glycol (PEG).
[0041] Preferably, the polyethylene glycol (PEG) is one or more selected from, but not limited to, PEG200, PEG300, PEG400, PEG600 and PEG800; more preferably, the polyethylene glycol (PEG) is PEG300 and / or PEG400.
[0042] Preferably, said stabilizer 1 is a poloxamer (P), more preferably, said stabilizer 1 is one or more selected from, but not limited to, P124, P188, P237, P338 and P407; even more preferably, said stabilizer 1 is P188.
[0043] Preferably, the stabilizer 2 is povidone (PVP), more preferably, the stabilizer 2 is one or more selected from, but not limited to, PVPK12, PVPK15, PVPK17, PVPK25, PVPK30 and PVPK45; even more preferably, the stabilizer 2 is PVPK12 and / or PVPK17.
[0044] Preferably, the additives include, but are not limited to, citric acid and / or tartaric acid; and / or acetic acid; and / or hydrochloric acid; and / or phosphoric acid; and / or lactic acid; and / or ascorbic acid; and / or L-cysteine; and / or sodium bisulfite; and / or sodium metabisulfite; and / or disodium edetate, more preferably, the additive is citric acid.
[0045] Preferably, the composition is in the form of an aqueous solution or a lyophilized solid suitable for storage.
[0046] In another aspect, the present invention provides a method for preparing the above-mentioned injectable composition containing docetaxel, the method comprising the steps of: Weighing out cyclodextrin into a container, adding co-solvent and water thereto, stirring the obtained system at 20°C-50°C, preferably 25°C, to dissolve, then adding stabilizer 1, stabilizer 2 and additives to the container, stirring them continuously to dissolve, then adding docetaxel to the container, stirring for another 30-480 minutes with or without nitrogen filling, after which docetaxel is dispersed and dissolved by stirring, finally obtaining a homogeneous mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2 μm microporous membrane after the sample is certified as acceptable, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. (first method); Preferably, the method comprises the following steps: Weighing the co-solvent into a container, then adding docetaxel thereto, stirring the obtained system at 20°C-50°C, preferably 25°C, until docetaxel is uniformly dispersed in the co-solvent, adding cyclodextrin to the container, continuously stirring to disperse it, then adding water thereto, after stirring the system thoroughly, adding stabilizer 1, stabilizer 2 and additives to the container, stirring the system for further 30-480 minutes after dissolving by stirring with or without nitrogen filling the container, finally obtaining a homogeneous mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2 μm microporous membrane after the sample is certified qualified, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. (second method); More preferably, the method comprises the steps of: Weighing out cyclodextrin, co-solvent, stabilizer 1, stabilizer 2, additives and water into a homogenizer, treating them with high pressure homogenization at 20°C-50°C and 1.0MPa-200MPa, preferably 25°C and 100MPa for 5-30 minutes (10-30 cycles) to obtain a uniformly dispersed and dissolved system, adding docetaxel to the system and treating it with high pressure homogenization for another 5-60 minutes, and finally obtaining a uniform mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2μm microporous membrane after the sample is certified as acceptable, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. (third method); Most preferably, the method comprises the steps of: Weighing the co-solvent into a homogenizer, adding docetaxel thereto, then processing them by high pressure homogenization at 20°C-50°C and 1.0MPa-200MPa, preferably 25°C and 100MPa for 5-30 minutes (10-30 cycles) to disperse, suspend or dissolve docetaxel in the co-solvent, then adding cyclodextrin, stabilizer 1, stabilizer 2, additives and water thereto, processing them by high pressure homogenization for another 5-60 minutes, finally obtaining a homogenous mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2μm microporous membrane after the sample is certified as acceptable, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. (fourth method), The pH value of the homogenous mixture obtained by the above methods (first method to fourth method) is 3.0 to 6.0, preferably 4.0 to 5.0; The above-mentioned methods, ie, the first method to the fourth method, are methods for preparing aqueous solutions intended to be stored in liquid form.
[0047] Further, the method of the present invention comprises the steps of: dispensing the filtrate obtained by filtering the mixture through a microporous membrane into vials; semi-sealing the vials with stoppers; then placing the vials in a freeze-drying freezer; then removing the vials and sealing them with stoppers, with or without nitrogen blanketing; then capping and labeling the vials. The method is for preparing a freeze-dried solid suitable for storage.
[0048] Through the general stirring method used in the preparation of the formulation, the formulation of docetaxel of the present invention with good solubility and longer stable time (after reconstitution) that meets clinical requirements can be prepared without using stabilizer 1, T-80 and ethanol.Then, the inventors further improve the preparation method and / or introduce the high pressure homogenization method used in nanocrystal technology, thereby obtaining the formulation of docetaxel with further improved solubility and stable storage for a long time.In addition, the production cost caused by the longer preparation time and the risk of microbial and impurity incorporation can be avoided by using the above-mentioned improved preparation method or introducing the high pressure homogenization method therein.In addition, if a certain amount of stabilizer 1 is introduced based on the improved preparation method, the beneficial effect of this formulation can be further amplified.
[0049] In the present invention, the cosolvent has the function of assisting dissolution and dispersion, the cyclodextrin has the function of solubilization and stabilization achieved by inclusion action, and the stabilizer can suppress the crystal growth of docetaxel in the composition and stabilize the entire composition system. Moreover, the above-mentioned dissolution, dispersion assistance, solubilization, stabilization, and suppression achieved by inclusion reaction can work synergistically, and they can be further enhanced by improving the preparation method of the composition and / or introducing high-pressure homogenization therein. In addition, under the conditions of suitable pH, low concentration of metal ions, and low or nearly low oxygen formed by adding injection additives, the injectable composition containing docetaxel provided by the present invention can have excellent stability even without polysorbate and ethanol. Specifically, the composition of the present invention has a longer stability time after reconstitution and can be stably stored for more than 24 months. Moreover, the composition is characterized by low anaphylaxis and irritation, and will not cause adverse effects caused by ethanol. The compositions of the present invention meet the standards for injectable docetaxel as set by the USP.
[0050] The composition of the present invention does not have polysorbate or ethanol, and can cause low histamine release, so there is no need to administer antihistamines, corticosteroids and H2 antagonists before administering the composition.The composition also has the advantages of high solubility of docetaxel, high stability, longer stability time after reconstitution and convenient clinical use.In addition, during administration of the composition, the risk of anaphylaxis, irritation, intoxication, intoxication, etc. is greatly reduced because it does not contain polysorbate and ethanol.In addition, the present invention also provides a method for preparing an injectable composition containing docetaxel. [The present invention 1001] An injectable composition containing docetaxel, the composition comprising the following components (in parts by weight): 1 part docetaxel, 20-60 parts cyclodextrin, 5-80 parts co-solvent, 0-20 parts stabilizer 1, 0.2-30 parts stabilizer 2, 0.001-1.0 parts additive and is free of ethanol and polysorbate, wherein no ethanol is used in the preparation thereof. [The present invention 1002] The composition comprises the following components (in parts by weight): 1 part docetaxel, 25-50 parts cyclodextrin, 20-70 parts cosolvent, 0-10 parts stabilizer 1, 1-15 parts stabilizer 2, 0.001-0.5 parts additive and is free of ethanol and polysorbates, wherein no ethanol is used in its preparation; Preferably, the composition comprises the following components (in parts by weight): 1 part docetaxel, 25-40 parts cyclodextrin, 40-70 parts cosolvent, 0-5 parts stabilizer 1, 4-9 parts stabilizer 2, 0.001-0.4 parts additive and is free of ethanol and polysorbates, wherein no ethanol is used in its preparation; More preferably, the composition comprises the following components (in parts by weight): 1 part docetaxel, 30-40 parts cyclodextrin, 50-65 parts co-solvent, 1-2 parts stabilizer 1, 5-8 parts stabilizer 2, 0.001-0.3 parts additive and is free of ethanol and polysorbates, and no ethanol is used in its preparation; The composition of the present invention 1001. [The present invention 1003] The composition of any one of claims 1001 and 1002, wherein the cyclodextrin includes, but is not limited to, sulfobutylether-β-cyclodextrin (SBE-β-CD), hydroxypropyl-β-cyclodextrin (HP-β-CD) and / or hydroxypropyl-sulfobutylether-β-cyclodextrin (HP-SBE-β-CD); more preferably, the cyclodextrin is HP-β-CD or SBE-β-CD; and even more preferably, the cyclodextrin is SBE-β-CD. [The present invention 1004] The co-solvent is one or more selected from, but not limited to, polyethylene glycol (PEG), propylene glycol, and glycerol, and the co-solvent is not ethanol; more preferably, the co-solvent is polyethylene glycol (PEG); Preferably, the polyethylene glycol (PEG) is one or more selected from, but not limited to, PEG200, PEG300, PEG400, PEG600 and PEG800; more preferably, the polyethylene glycol (PEG) is PEG300 and / or PEG400. The composition of any one of 1001 to 1003 according to the present invention. [The present invention 1005] Any of the compositions of the present inventions 1001 to 1004, wherein the stabilizer 1 is a poloxamer (P), more preferably, the stabilizer 1 is one or more selected from, but not limited to, P124, P188, P237, P338 and P407; and even more preferably, the stabilizer 1 is P188. [The present invention 1006] Any of the compositions of present inventions 1001 to 1005, wherein the stabilizer 2 is povidone (PVP), more preferably, the stabilizer 2 is one or more selected from, but not limited to, PVPK12, PVPK15, PVPK17, PVPK25, PVPK30 and PVPK45; and even more preferably, the stabilizer 2 is PVPK12 and / or PVPK17. [The present invention 1007] Any of the compositions according to inventions 1001 to 1006, wherein the additive includes, but is not limited to, citric acid and / or tartaric acid; and / or acetic acid; and / or hydrochloric acid; and / or phosphoric acid; and / or lactic acid; and / or ascorbic acid; and / or L-cysteine; and / or sodium bisulfite; and / or sodium metabisulfite; and / or disodium edetate, and more preferably, the additive is citric acid. [The present invention 1008] Any of the compositions of the present invention 1001 to 1007, which is in the form of an aqueous solution or a lyophilized solid suitable for storage, Preferably, the composition, which is in the form of an aqueous solution suitable for storage, is prepared by the following steps: Weighing out cyclodextrin into a container, adding co-solvent and water thereto, stirring the obtained system at 20°C-50°C, preferably 25°C, to dissolve, then adding stabilizer 1, stabilizer 2 and additives to the container, stirring them continuously to dissolve, then adding docetaxel to the container, stirring for another 30-480 minutes with or without nitrogen filling, after which docetaxel is dispersed and dissolved by stirring, finally obtaining a homogeneous mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2 μm microporous membrane after the sample is certified as acceptable, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. prepared by a process comprising: More preferably, the method comprises the steps of: Weighing the co-solvent into a container, then adding docetaxel thereto, stirring the obtained system at 20°C-50°C, preferably 25°C, until docetaxel is uniformly dispersed in the co-solvent, adding cyclodextrin to the container, continuously stirring to disperse it, then adding water thereto, after stirring the system thoroughly, adding stabilizer 1, stabilizer 2 and additives to the container, stirring the system for further 30-480 minutes after dissolving by stirring with or without nitrogen filling the container, finally obtaining a homogeneous mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2 μm microporous membrane after the sample is certified qualified, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. Includes; More preferably, the method comprises the steps of: Weighing out cyclodextrin, co-solvent, stabilizer 1, stabilizer 2, additives and water into a homogenizer, treating them with high pressure homogenization at 20°C-50°C and 1.0MPa-200MPa, preferably 25°C and 100MPa for 5-30 minutes (10-30 cycles) to obtain a uniformly dispersed and dissolved system, adding docetaxel to the system and treating it with high pressure homogenization for another 5-60 minutes, and finally obtaining a uniform mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2μm microporous membrane after the sample is certified as acceptable, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. Includes; Most preferably, the method comprises the steps of: Weighing the co-solvent into a homogenizer, adding docetaxel thereto, then treating them with high pressure homogenization at 20°C-50°C and 1.0MPa-200MPa, preferably 25°C and 100MPa for 5-30 minutes (10-30 cycles) to disperse, suspend or dissolve docetaxel in the co-solvent, then adding cyclodextrin, stabilizer 1, stabilizer 2, additives and water thereto, treating them with high pressure homogenization for another 5-60 minutes, finally obtaining a homogenous mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2μm microporous membrane after the sample is certified as acceptable, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. Includes; The pH value of the homogenous mixture obtained by the above method is 3.0 to 6.0, preferably 4.0 to 5.0; Even more preferably, the composition in the form of a freeze-dried solid suitable for storage is prepared by the following steps: dispensing the filtrate obtained by filtering the mixture through a 0.2 μm microporous membrane into vials; semi-sealing the vials with stoppers; then placing the vials in a freeze dryer for lyophilization; then removing the vials and sealing them with stoppers with or without nitrogen blanketing; then capping and labeling the vials. prepared by a process comprising: composition. [The present invention 1009] The following steps: Weighing out cyclodextrin into a container, adding co-solvent and water thereto, stirring the obtained system at 20°C-50°C, preferably 25°C, to dissolve, then adding stabilizer 1, stabilizer 2 and additives to the container, stirring them continuously to dissolve, then adding docetaxel to the container, stirring for another 30-480 minutes with or without nitrogen filling, after which docetaxel is dispersed and dissolved by stirring, finally obtaining a homogeneous mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2 μm microporous membrane after the sample is certified as acceptable, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. Includes; Preferably, the method comprises the steps of: Weighing the co-solvent into a container, then adding docetaxel thereto, stirring the obtained system at 20°C-50°C, preferably 25°C, until docetaxel is uniformly dispersed in the co-solvent, adding cyclodextrin to the container, continuously stirring to disperse it, then adding water thereto, after stirring the system thoroughly, adding stabilizer 1, stabilizer 2 and additives to the container, stirring the system for further 30-480 minutes after dissolving by stirring with or without nitrogen filling the container, finally obtaining a homogeneous mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2 μm microporous membrane after the sample is certified qualified, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. Includes; More preferably, the steps are: Weighing out cyclodextrin, co-solvent, stabilizer 1, stabilizer 2, additives and water into a homogenizer, treating them with high pressure homogenization at 20°C-50°C and 1.0MPa-200MPa, preferably 25°C and 100MPa for 5-30 minutes (10-30 cycles) to obtain a uniformly dispersed and dissolved system, adding docetaxel to the system and treating it with high pressure homogenization for another 5-60 minutes, and finally obtaining a uniform mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2μm microporous membrane after the sample is certified as acceptable, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. Includes; Most preferably, the method comprises the steps of: Weighing the co-solvent into a homogenizer, adding docetaxel thereto, then treating them with high pressure homogenization at 20°C-50°C and 1.0MPa-200MPa, preferably 25°C and 100MPa for 5-30 minutes (10-30 cycles) to disperse, suspend or dissolve docetaxel in the co-solvent, then adding cyclodextrin, stabilizer 1, stabilizer 2, additives and water thereto, treating them with high pressure homogenization for another 5-60 minutes, finally obtaining a homogenous mixture; sampling a sample from the obtained mixture to determine the pH value and docetaxel content in the sample, then filtering the mixture through a 0.2μm microporous membrane after the sample is certified as acceptable, dispensing the obtained filtrate into vials, sealing the vials with or without nitrogen filling, then capping and labeling the vials. Includes; The pH value of the homogeneous mixture obtained by the above method is 3.0 to 6.0, preferably 4.0 to 5.0. A method for preparing any one of the compositions of the present inventions 1001 to 1008. [The present invention 1010] The following steps: Dispensing the filtrate obtained by filtering the mixture through a 0.2 μm microporous membrane as in the present invention 1009 into vials, semi-sealing the vials with stoppers, then placing the vials in a freeze dryer for lyophilization, then removing the vials and sealing them with stoppers with or without nitrogen filling, then capping and labeling the vials. The method of the present invention 1009 further comprises: DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0051] Detailed Description The present invention will be further described in detail in combination with the following specific embodiments. Those skilled in the art will recognize that the embodiments provided in no way limit the scope of the present invention, but are used only to illustrate the present invention.
[0052] Stability time after reconstitution: This is an important indicator for investigating whether a poorly soluble drug can be prepared into a formulation that meets the requirements for clinical use. In general, if the stability time of the dilution of the formulation when used clinically is ≧4 hours, it can be considered to meet the general clinical requirements. In this situation, the stability time after reconstitution is determined as follows: Sample an appropriate amount of the solution prepared in the example according to the concentration of API in the solution, add 5% glucose injection or saline thereto to dilute the solution containing docetaxel to a concentration of 0.5mg / mL commonly used in clinical practice, and observe the resulting dilution with a lamp detector to determine whether there is crystal precipitation, and record the time when crystallization begins as the stability time. EXAMPLES
[0053] Example experiment description: Since the present invention does not use polysorbate and ethanol, it is necessary to screen the amount and type of cyclodextrin, co-solvent and stabilizer contained in the whole solution system.Since docetaxel is a poorly soluble drug, it is important to consider whether docetaxel is dissolved, how much it is dissolved, and the stabilization time after dissolution.Based on this, the inventors conducted experiments with the following indicators: whether a solution can be formed, the solubility of docetaxel and the stabilization time after reconstitution.The specific work to determine the solubility is as follows:
[0054] Weigh out components (without docetaxel) and excess docetaxel (API) according to the ratio listed in corresponding examples, prepare supersaturated solution according to corresponding preparation method, filter and dilute the supersaturated solution, and then determine the solubility of docetaxel in the obtained filtrate.For details of this content, please refer to Experimental Examples 1-99.
[0055] a) Methods for determining solubility: The solubility is determined according to the determination criteria for injectable docetaxel set by the USP, specifically as follows: High-performance liquid chromatography Solution A: Water Solution B: Acetonitrile Mobile phase: TIFF0007577364000002.tif64140 Solvent: acetonitrile: acetic acid: water = 100:0.1:100 Chromatographic conditions: Detector: UV232nm Column: 4.6mm x 150mm; 3.5μm, L1 Temperature: Column temperature 45℃ Flow rate: 1.2mL / min Injection volume: 20μL
[0056] Control solution: 0.2 mg / mL standard docetaxel. Specifically, 10 mg of standard docetaxel is accurately weighed and then placed into a 50 mL flask, and then the standard docetaxel is diluted with the solvent to the dotted line.
[0057] Test solution: Accurately weigh out an appropriate amount of sample containing docetaxel. Then, dilute the sample with a solvent until the concentration of docetaxel is 0.2 mg / mL.
[0058] Examples 1 to 11 and Experimental Examples 1 to 11 The first method was used in these examples, and the amount of stabilizer 1 added was 0. Specifically: Cyclodextrin was weighed into a container, co-solvent and water were added thereto, and the resulting system was stirred and dissolved at 20℃-50℃ (see the table below for specific temperature), then stabilizer 1, stabilizer 2 and additives were added to the container, and they were continuously stirred and dissolved, and then docetaxel was added to the container, and the system was stirred for another 30-480 minutes with or without nitrogen filling, after docetaxel was dispersed and dissolved by stirring, and finally a homogeneous mixture was obtained; a sample was sampled from the resulting mixture to determine the pH value and the docetaxel content in the sample, and then the mixture was filtered through a 0.2μm microporous membrane after the sample was certified as qualified, and then the obtained filtrate was dispensed into a vial, and then the vial was sealed with a stopper, capped and labeled with or without nitrogen filling. TIFF0007577364000003.tif252113
[0059] Examples 12 to 22 and Experimental Examples 12 to 22 The second method was used in these examples, and the amount of Stabilizer 1 added was 0. Specifically: the co-solvent was weighed into a container, then docetaxel was added thereto, and the resulting system was stirred at 20°C-50°C (see the table below for specific temperatures) until docetaxel was uniformly dispersed in the co-solvent, then cyclodextrin was added to the container, and continued stirring was used to disperse it, then water was added, and after sufficient stirring, Stabilizer 1, Stabilizer 2 and additives were added to the container, and the container was filled with or without nitrogen, and the resulting system was stirred for another 30-480 minutes after stirring to dissolve, and finally a homogeneous mixture was obtained. Samples were taken from the resulting mixture to determine the pH value and the docetaxel content in the sample, and then the mixture was filtered through a 0.2 μm microporous membrane after the sample was certified as qualified, and then the resulting filtrate was dispensed into vials, and then the vials were filled with or without nitrogen, sealed with stoppers, capped and labeled. TIFF0007577364000004.tif252106
[0060] Experimental Examples 23 to 33 and Experimental Examples 23 to 33 The third method was used in these examples, and the amount of stabilizer 1 added was 0. Specifically: Cyclodextrin, co-solvent, stabilizer 1, stabilizer 2, additives and water were weighed into a homogenizer, then they were processed by high-pressure homogenization at 20℃-50℃ and 1MPa-200MPa (see the table below for specific temperature and pressure) for 5-30 minutes (10-30 cycles) to obtain a uniformly dispersed and dissolved system, then docetaxel was added to the system and processed by high-pressure homogenization for another 5-60 minutes, finally a uniform mixture was obtained; a sample was sampled from the obtained mixture to determine the pH value and the docetaxel content in the sample, then the mixture was filtered through a 0.2μm microporous membrane after the sample was certified as acceptable, then the obtained filtrate was dispensed into vials, the vials were sealed with stoppers with or without nitrogen filling, capped and labeled. TIFF0007577364000005.tif252114
[0061] Experimental Examples 34 to 44 and Experimental Examples 34 to 44 The fourth method was used in these examples, and the amount of Stabilizer 1 added was 0. Specifically: the co-solvent was weighed into a homogenizer, docetaxel was added thereto, and then the mixture was processed by high-pressure homogenization at 20°C-50°C and 1MPa-200MPa (see the table below for specific temperature and pressure) for 5-30 minutes (10-30 cycles) to disperse, suspend or dissolve docetaxel in the co-solvent, then cyclodextrin, stabilizer 1, stabilizer 2, additives and water were added into the homogenizer, and the mixture was processed by high-pressure homogenization for another 5-60 minutes, and finally a homogeneous mixture was obtained; a sample was sampled from the obtained mixture to determine the pH value and the docetaxel content in the sample, and then the mixture was filtered through a 0.2μm microporous membrane after the sample was certified as qualified, and then the obtained filtrate was dispensed into vials, and the vials were sealed with stoppers with or without nitrogen filling, capped and labeled. TIFF0007577364000006.tif247108
[0062] Experimental Examples 45-55 and Experimental Examples 45-55 The first method was used in these examples, and the amount of stabilizer 1 added was other than 0. Specifically: Cyclodextrin was weighed into a container, co-solvent and water were added thereto, and the resulting system was stirred and dissolved at 20℃-50℃ (see the table below for the specific temperature), then stabilizer 1, stabilizer 2 and additives were added to the container, and they were continuously stirred and dissolved, after which docetaxel was added to the container, and the system was stirred for another 30-480 minutes with or without nitrogen filling, after docetaxel was dispersed and dissolved by stirring, and finally a homogeneous mixture was obtained; a sample was taken from the resulting mixture to determine the pH value and the docetaxel content in the sample, and then the mixture was filtered through a 0.2μm microporous membrane after the sample was certified as qualified, and then the resulting filtrate was dispensed into vials, and then the vials were sealed with stoppers, capped and labeled with or without nitrogen filling. TIFF0007577364000007.tif247108
[0063] Experimental Examples 56 to 66 and Experimental Examples 56 to 66 The second method was used in these examples, and the amount of Stabilizer 1 added was other than 0. Specifically: the co-solvent was weighed into a container, then docetaxel was added thereto, and the resulting system was stirred at 20°C-50°C (see the table below for specific temperatures) until docetaxel was uniformly dispersed in the co-solvent, then cyclodextrin was added to the container and stirred continuously to disperse it, then water was added, and after stirring sufficiently, Stabilizer 1, Stabilizer 2 and additives were added to the container, and the container was filled with or without nitrogen, and the resulting system was stirred for another 30-480 minutes after stirring to dissolve, and finally a homogeneous mixture was obtained. Samples were sampled from the resulting mixture to determine the pH value and the docetaxel content in the sample, and then the mixture was filtered through a 0.2 μm microporous membrane after the sample was certified as qualified, and then the resulting filtrate was dispensed into vials, and the vials were filled with or without nitrogen, sealed with stoppers, capped and labeled. TIFF0007577364000008.tif247108
[0064] Experimental Examples 67-77 and Experimental Examples 67-77 The third method was used in these examples, and the amount of stabilizer 1 added was other than 0. Specifically: Cyclodextrin, co-solvent, stabilizer 1, stabilizer 2, additives and water were weighed into a homogenizer, then they were processed by high-pressure homogenization at 20℃-50℃ and 1MPa-200MPa (see the table below for specific temperature and pressure) for 5-30 minutes (10-30 cycles) to obtain a uniformly dispersed and dissolved system, then docetaxel was added to the system and processed by high-pressure homogenization for another 5-60 minutes, finally a uniform mixture was obtained; a sample was sampled from the obtained mixture to determine the pH value and the docetaxel content in the sample, then the mixture was filtered through a 0.2μm microporous membrane after the sample was certified as acceptable, then the obtained filtrate was dispensed into vials, then the vials were sealed with stoppers with or without nitrogen filling, capped and labeled. TIFF0007577364000009.tif247108
[0065] Experimental Examples 78-88 and Experimental Examples 78-88 The fourth method was used in these examples, and the amount of stabilizer 1 added was other than 0. Specifically: the co-solvent was weighed into a homogenizer, docetaxel was added thereto, and then the mixture was processed by high-pressure homogenization at 20°C-50°C and 1MPa-200MPa (see the table below for specific temperature and pressure) for 5-30 minutes (10-30 cycles) to disperse, suspend or dissolve docetaxel in the co-solvent, then cyclodextrin, stabilizer 1, stabilizer 2, additives and water were added into the homogenizer, and the mixture was processed by high-pressure homogenization for another 5-60 minutes, and finally a homogeneous mixture was obtained; a sample was sampled from the obtained mixture to determine the pH value and the docetaxel content in the sample, and then the mixture was filtered through a 0.2μm microporous membrane after the sample was certified as qualified, and then the obtained filtrate was dispensed into vials, and then the vials were sealed with stoppers, capped and labeled with or without nitrogen filling. TIFF0007577364000010.tif247108
[0066] Experimental Examples 89-99 and Experiments 89-99 In Examples 89-99, the fourth method was used by screening the types of co-solvents, stabilizers and additives. Specifically: the co-solvent is weighed into a homogenizer, docetaxel is added thereto, and then processed by high-pressure homogenization at 20℃-50℃ and 1MPa-200MPa (see the table below for specific temperature and pressure) for 5-30 minutes (10-30 cycles) to disperse, suspend or dissolve docetaxel in the co-solvent, then cyclodextrin, stabilizer 1, stabilizer 2, additives and water are added into the homogenizer, and processed by high-pressure homogenization for another 5-60 minutes, and finally a homogeneous mixture is obtained; a sample is sampled from the obtained mixture to determine the pH value and the docetaxel content in the sample, and then the mixture is filtered through a 0.2μm microporous membrane after the sample is certified as qualified, and then the obtained filtrate is dispensed into vials, and then the vials are sealed with stoppers with or without nitrogen filling, capped and labeled. TIFF0007577364000011.tif249117
[0067] Example 100 Docetaxel 0.2g SBE-β-CD 7.0g PEG300 12.0g P188 0.3g PVPK12 1.6g Citric acid 2mg water 5.0g The composition of this embodiment is prepared by the fourth method.Specifically: co-solvent is weighed into homogenizer, docetaxel is added thereto, then processed by high-pressure homogenization at 25℃ and 100MPa for 5 minutes, so that docetaxel is dispersed, suspended or dissolved in co-solvent, then cyclodextrin, stabilizer 1, stabilizer 2, additive and water are added into homogenizer, processed by high-pressure homogenization for another 30 minutes, finally obtain a homogeneous mixture; Sample is taken from the obtained mixture to determine pH value and docetaxel content in the sample, then the mixture is filtered through 0.2μm microporous membrane after the sample is certified as acceptable, then the obtained filtrate is dispensed into vial, then the vial is sealed with stopper with or without nitrogen filling, capped and labeled. Stability time after reconstitution: 24 hours.
[0068] In order to demonstrate the inventive step of the present invention, the present inventors have carried out comparative examples and related experimental examples as follows.
[0069] Comparative Examples 1 to 7 The compositions of these comparative examples are prepared by the fourth method. Specifically: co-solvent is weighed into homogenizer, docetaxel is added thereto, and then processed by high-pressure homogenization at 25°C and 100MPa for 5 minutes to disperse, suspend or dissolve docetaxel in the co-solvent, then cyclodextrin, stabilizer 1, stabilizer 2, additives and water are added into homogenizer, and processed by high-pressure homogenization for another 30 minutes, and finally a homogeneous mixture is obtained; a sample is sampled from the obtained mixture to determine the pH value and the docetaxel content in the sample, and then the mixture is filtered through a 0.2μm microporous membrane after the sample is certified as acceptable, and then the obtained filtrate is dispensed into vials, and then the vials are sealed with stoppers with or without nitrogen filling, capped and labeled. In addition, the stability time of the compositions prepared by these comparative examples is studied, and the maximum concentration of API is further determined by adding excess API compared to those listed in these comparative examples according to the method described in the experimental examples.
[0070] Comparative Example 8 This comparative example was carried out according to Examples 1 and 4 disclosed in US Patent No. 8675716B2 / CN100411688C. Specifically, 1.7g of SBE-β-CD was mixed with 5.0ml of pure water, and then a solution prepared by 100mg of docetaxel and ethanol was slowly added dropwise under stirring. After thorough mixing until complete dissolution, the resulting mixture was filtered through a 0.2μm microporous membrane. Ethanol was removed from the filtrate under reduced pressure at 55℃. After sterilization, water was also removed under reduced pressure until dry, and then the resulting solid product was dried under reduced pressure for 48 hours to give a white solid inclusion. In addition, the stability time of the composition prepared according to this comparative example was studied, and the maximum concentration of API was further determined by adding excess API compared to that listed in this comparative example according to the method described in the experimental example.
[0071] The results of Comparative Examples 1 to 8 are shown below. TIFF0007577364000012.tif111170
[0072] Experimental Example 100 The ethanol content was determined by gas chromatography as follows. Chromatographic conditions: Column: InertCap 624 (stationary phase liquid: G43, length: 60 m; ID: 0.25 mm, 1.4 μm, Shimadzu); Detector: Flame ionization detector (FID); Carrier gas: nitrogen; Linear speed: 21.5cm / s; Total flow rate: 24.0mL / min; Column flow rate: 1mL / min Purge flow rate: 3.0mL / min; Split ratio: 20:1. Temperature programmed conditions: initial temperature 50° C. held for 5 min, then temperature increased at 10° C. / min to 200° C., held for 4 min, then sampled; total run time 24 min. Injection temperature: 210℃; FID temperature: 280℃. Sampling size: 1μL Detection limit: 5.057ng Limit of quantification: 1.264ng.
[0073] The content of ethanol in the samples prepared in Examples 9, 86 and Comparative Example 8 was determined according to the above description. The results are summarized as follows: TIFF0007577364000013.tif33151
[0074] These results indicate that the ethanol used to enhance the dissolution of docetaxel cannot be completely removed under reduced pressure. In this regard, the composition prepared in US8675716B2 / CN100411688C should contain ethanol.
[0075] Experimental Example 101 Stability studies of liquid compositions: The compositions were prepared according to the method described in patent US8675716B2. Specifically, ethanol was added during preparation to improve the dissolution of docetaxel, and then most of the ethanol and water were removed under reduced pressure to obtain a solid inclusion complex (i.e., composition). Furthermore, new injectable liquid compositions (compositions 1-4) containing 10 mg / mL docetaxel were prepared using the solid inclusion complex and the injectable carrier used in the present invention, and then the stability time of the liquid compositions and the stability time after reconstitution were studied.
[0076] Other samples were an injectable composition containing 10 mg / mL docetaxel prepared according to the method disclosed in patent application WO2016 / 149162, and an injectable composition containing 10 mg / mL docetaxel prepared according to Example 86 of the present invention. The specific formulations are as follows:
[0077] Composition 1: Docetaxel 100mg SBE-β-CD 3.5g Ethanol (appropriate amount) Appropriate amount of water The ethanol and most of the water were removed under reduced pressure to give a solid composition which was then reconstituted into a liquid composition using the following materials: water 7.0g
[0078] Composition 2: Docetaxel 100mg SBE-β-CD 3.5g Ethanol (appropriate amount) Appropriate amount of water The ethanol and most of the water were removed under reduced pressure to give a solid composition which was then reconstituted into a liquid composition using the following materials: PEG300 6.0g Citric acid 2mg 2.5g water
[0079] Composition 3: Docetaxel 100mg SBE-β-CD 3.5g Ethanol (appropriate amount) Appropriate amount of water The ethanol and most of the water were removed under reduced pressure to give a solid composition which was then reconstituted into a liquid composition using the following materials: P188 150mg PVPK12 800mg Citric acid 2mg 2.5g water
[0080] Composition 4: Docetaxel 100mg SBE-β-CD 3.5g Ethanol (appropriate amount) Appropriate amount of water The ethanol and most of the water were removed under reduced pressure to give a solid composition which was then reconstituted into a liquid composition using the following materials: PEG300 6.0g P188 150mg PVPK12 800mg Citric acid 2mg 2.5g water
[0081] The results are summarized as follows: TIFF0007577364000014.tif64137
[0082] From the above results, it can be seen that as long as ethanol (which is subsequently removed) is used during the preparation of the solid composition in the method described in patent US8675716B2, compositions 1-4 (liquid form) have a significantly shortened stability time (after reconstitution), even if they are obtained by reconstituting the solid composition with the co-solvent and stabilizer used in the present invention. This suggests that the difference in the preparation method or the type of co-solvent leads to a significant difference in the stability of the composition of the present invention and the composition of US8675716B2, i.e., a stable solution formulation suitable for clinical use cannot be obtained through US8675716B2. In addition, the above significant difference can be observed even between compositions having 99% identical ingredients to the composition of the present invention (the composition prepared according to US8675716B2 contains a small amount of ethanol), which shows that even a difference of only 1.0% in the ingredients (i.e., a small to trace amount of ethanol is present) or preparation method can greatly affect the stability of the obtained composition. The inventors have found that there is a unique synergistic effect between the components of the composition of the present invention, but this effect is not self-evident, since it was unexpected before the experiment without ethanol was performed. This is also confirmed by the composition containing ethanol with an ethanol to API ratio of 5:1 to 40:1 prepared according to WO2016 / 149162. The composition of WO2016 / 149162 can also achieve the same technical effect as that of the present invention due to having more ethanol in it. However, in clinical applications, ethanol is not recommended by the FDA due to the safety issues it brings. Therefore, from the perspective of safety for clinical use, the composition of the present invention has a very obvious advantage.
[0083] Experimental Example 102 2000 mL of samples were prepared according to the method of Example 86 and then placed under conditions of 25° C.±2° C. and RH 60%±5% for long-term stability studies. The samples were tested according to USP standards as follows: Chromatographic conditions: Detection wavelength: 232 nm Column temperature: 45°C Flow rate: 1.2ml / min Sample size: 20μL Solvent: acetonitrile:water=1:1 Mobile phase A is water and mobile phase B is acetonitrile. The elution gradient is shown in the table below. HPLC gradients for detecting the content and related substances of docetaxel for injection TIFF0007577364000015.tif55167
[0084] result: TIFF0007577364000016.tif181168Note: a: 10-deacetylbaccatin b: 2-debenzoyl-2-pentenoyl docetaxel c: Crotonaldehyde analogues d: 6-oxo-docetaxel e: 4-epi-docetaxel f: 4-epido-6-oxodocetaxel
[0085] Conclusion: The following conclusions can be drawn from the results of the above Examples, Experimental Examples, and Comparative Examples.
[0086] a) There is a synergistic effect between cyclodextrin, cosolvent and stabilizer, through which the solubility of API in injection solution can be increased and the stability time after reconstitution of the composition can be improved. The amount of stabilizer 2 and cyclodextrin added is positively correlated with the stability time after reconstitution, that is, the more the amount added, the longer the stability time after reconstitution. However, taking into account the safety and stability of these carriers themselves, and considering meeting the requirements of clinical drug application, improving safety and reducing costs, the inventors select the appropriate amount of both carriers.
[0087] b) Regarding stabilizer 1: The compositions prepared by the first to fourth methods can basically meet the clinical use requirements when the amount of stabilizer 1 added is 0. However, even if an appropriate amount of stabilizer 1 is added, the compositions prepared by the same methods and with the same other ingredients have better effects than those when the amount of stabilizer 1 is 0. Furthermore, if the methods are further improved, the effects will be more obvious.
[0088] c) Regarding co-solvents: Co-solvents have a crucial effect on whether an API can be formulated into a solution form. In fact, if no co-solvent is added, the API cannot be formulated into a solution form. However, the amount of co-solvent added is not unlimited, and it should be considered that the amount of co-solvent added can not only assist the dissolution of the API, but also obtain a solution of appropriate concentration to meet clinical requirements;
[0089] d) Regarding preparation method: In the preparation of the composition by the first method to the fourth method, it is found that the improvement of the present method can greatly increase the solubility of the API in the composition, can shorten the preparation time, and can reduce the production cost and the risk of incorporation of microorganisms and impurities caused by the longer preparation time.
[0090] e) In view of the safety of the pharmaceutical preparation, the type or amount of medical carrier should be as small as possible, and the type of carrier should be that which is commonly used in the prior art and meets the requirements for injection. When the amount of cyclodextrin, cosolvent and stabilizer is in the preferred range, the effect of the composition obtained thereby is equivalent to that of the composition obtained with cyclodextrin, cosolvent and stabilizer in a higher range. In other words, the effect of the composition is not significantly improved by further increasing the amount of cyclodextrin, cosolvent and stabilizer. Therefore, it is a better option to make their addition amount within the preferred range. For the selection of additives, it is better to strive to select a type of additive that meets the safety requirements of injection and the pH requirements of the preparation. Therefore, additives in the preferred range are a better option.
Claims
1. An injectable composition containing docetaxel, the composition comprising the following components (in parts by weight): 1 part docetaxel, 20-60 parts cyclodextrin, 5-80 parts cosolvent, 0-20 parts stabilizer 1, 0.2-30 parts stabilizer 2, 0.001-1.0 parts additive and is free of ethanol and polysorbates, wherein no ethanol is used in the preparation thereof; the composition is in the form of an aqueous solution suitable for storage; the co-solvent is polyethylene glycol (PEG) and / or propylene glycol; The stabilizer 1 is a poloxamer (P), The stabilizer 2 is povidone (PVP), The cyclodextrin is sulfobutyl ether-β-cyclodextrin (SBE-β-CD), The additives include citric acid; and / or tartaric acid; and / or acetic acid; and / or hydrochloric acid; and / or phosphoric acid; and / or lactic acid; and / or ascorbic acid; and / or L-cysteine; and / or sodium bisulfite; and / or sodium metabisulfite; and / or disodium edetate. The composition.
2. The composition comprises the following components (in parts by weight): 1 part docetaxel, 25-50 parts cyclodextrin, 20-70 parts cosolvent, 0-10 parts stabilizer 1, 1-15 parts stabilizer 2, 0.001-0.5 parts additive and is free of ethanol and polysorbate, and no ethanol is used in the preparation thereof.
3. The composition comprises the following components (in parts by weight): 1 part docetaxel, 25-40 parts cyclodextrin, 40-70 parts cosolvent, 0-5 parts stabilizer 1, 4-9 parts stabilizer 2, 0.001-0.4 parts additive and is free of ethanol and polysorbate, and no ethanol is used in its preparation.
4. The composition comprises the following components (in parts by weight): 1 part docetaxel, 30-40 parts cyclodextrin, 50-65 parts cosolvent, 1-2 parts stabilizer 1, 5-8 parts stabilizer 2, 0.001-0.3 parts additive and is free of ethanol and polysorbate, wherein no ethanol is used in the preparation thereof.
5. 2. The composition of claim 1, wherein the co-solvent is polyethylene glycol (PEG).
6. 6. The composition of claim 5, wherein the polyethylene glycol (PEG) is one or more selected from PEG200, PEG300, PEG400, PEG600 and PEG800.
7. The polyethylene glycol (PEG) is PEG300 and / or PEG400. The composition of claim 5.
8. 2. The composition of claim 1, wherein the stabilizer 1 is one or more selected from P124, P188, P237, P338 and P407.
9. 2. The composition of claim 1, wherein the stabilizer 1 is P188.
10. 2. The composition of claim 1, wherein the stabilizer 2 is one or more selected from PVPK12, PVPK15, PVPK17, PVPK25, PVPK30 and PVPK45.
11. The composition of claim 10, wherein the stabilizer 2 is PVPK12 and / or PVPK17.
12. 2. The composition of claim 1, wherein the additive is citric acid.
Citation Information
Patent Citations
Cabazitaxel composition for injection and preparation method thereof
CN108066774A
Pharmaceutical compositions containing cyclodextrins and taxoids
CN1222321C
Lyophilized solid taxane compositions, methods of producing said compositions, pharmaceutical formulations of said compositions, kits for the formulation of said compositions.
JP2009523771A
Stable pharmaceutical composition containing docetaxel and method for producing the same
JP2009538294A
A lyophilized pharmaceutical composition containing a taxane derivative with improved stability, and a method for producing the same.
JP2011523620A
